Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $15.02, for a total transaction of $66,088.00. Following the completion of the sale, the chief executive officer now owns 737,767 shares of the company’s stock, valued at $11,081,260.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) traded down 1.66% during midday trading on Friday, hitting $14.80. 70,105 shares of the stock traded hands. The stock’s market cap is $452.27 million. Atara Biotherapeutics, Inc. has a one year low of $11.80 and a one year high of $23.00. The company has a 50-day moving average price of $14.81 and a 200 day moving average price of $15.87.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.05. Equities research analysts anticipate that Atara Biotherapeutics, Inc. will post ($3.89) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Atara Biotherapeutics, Inc. (ATRA) CEO Sells $66,088.00 in Stock” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/09/08/atara-biotherapeutics-inc-atra-ceo-sells-66088-00-in-stock.html.

Several institutional investors have recently modified their holdings of ATRA. Teachers Advisors LLC boosted its holdings in shares of Atara Biotherapeutics by 5.5% in the 4th quarter. Teachers Advisors LLC now owns 137,416 shares of the biotechnology company’s stock valued at $1,951,000 after buying an additional 7,165 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Atara Biotherapeutics by 9.0% in the 1st quarter. Wells Fargo & Company MN now owns 58,252 shares of the biotechnology company’s stock valued at $1,197,000 after buying an additional 4,791 shares in the last quarter. Jennison Associates LLC acquired a new position in shares of Atara Biotherapeutics in the 1st quarter valued at $829,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Atara Biotherapeutics in the 1st quarter valued at $185,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Atara Biotherapeutics by 5.3% in the 1st quarter. Bank of New York Mellon Corp now owns 120,097 shares of the biotechnology company’s stock valued at $2,468,000 after buying an additional 6,069 shares in the last quarter. Institutional investors and hedge funds own 82.95% of the company’s stock.

Several research firms have recently commented on ATRA. BidaskClub downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. ValuEngine upgraded shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Canaccord Genuity set a $47.00 price objective on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, August 7th. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a research note on Thursday, June 22nd. Four equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $23.60.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.